Prabhu Rajagopalan

1.6k total citations
51 papers, 1.1k citations indexed

About

Prabhu Rajagopalan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Prabhu Rajagopalan has authored 51 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Prabhu Rajagopalan's work include Colorectal Cancer Treatments and Studies (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Prabhu Rajagopalan is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Prabhu Rajagopalan collaborates with scholars based in United States, Germany and France. Prabhu Rajagopalan's co-authors include Raymond F. Schinazi, F. Douglas Boudinot, Marc R. Gastonguay, Olaf Christensen, Fred Wudl, Hans Gelderblom, Neeltje Steeghs, Marcel M.C. Hovens, Jos Op ’t Roodt and Eelco J.P. de Koning and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Prabhu Rajagopalan

50 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Prabhu Rajagopalan United States 17 365 360 252 138 117 51 1.1k
Annamaria Catino Italy 22 329 0.9× 476 1.3× 453 1.8× 76 0.6× 88 0.8× 114 1.5k
Lucille Leong United States 23 502 1.4× 691 1.9× 265 1.1× 162 1.2× 169 1.4× 74 1.6k
Zaina T. Al-Salama New Zealand 17 322 0.9× 262 0.7× 174 0.7× 128 0.9× 120 1.0× 35 1.0k
Raffaele Longo Italy 19 567 1.6× 571 1.6× 297 1.2× 94 0.7× 62 0.5× 64 1.5k
Rakesh Goel Canada 20 376 1.0× 790 2.2× 287 1.1× 244 1.8× 183 1.6× 95 1.5k
Virginia E. Kwitkowski United States 16 484 1.3× 423 1.2× 264 1.0× 192 1.4× 43 0.4× 18 1.2k
Martin A. Graham United States 15 278 0.8× 540 1.5× 133 0.5× 183 1.3× 62 0.5× 21 1.3k
Yoichiro Kakugawa Japan 21 483 1.3× 625 1.7× 309 1.2× 96 0.7× 64 0.5× 52 1.4k
Jianwei Zhang China 16 359 1.0× 462 1.3× 185 0.7× 143 1.0× 45 0.4× 88 1.1k
Jiang Liu United States 16 426 1.2× 446 1.2× 149 0.6× 56 0.4× 86 0.7× 43 1.5k

Countries citing papers authored by Prabhu Rajagopalan

Since Specialization
Citations

This map shows the geographic impact of Prabhu Rajagopalan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prabhu Rajagopalan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prabhu Rajagopalan more than expected).

Fields of papers citing papers by Prabhu Rajagopalan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prabhu Rajagopalan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prabhu Rajagopalan. The network helps show where Prabhu Rajagopalan may publish in the future.

Co-authorship network of co-authors of Prabhu Rajagopalan

This figure shows the co-authorship network connecting the top 25 collaborators of Prabhu Rajagopalan. A scholar is included among the top collaborators of Prabhu Rajagopalan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prabhu Rajagopalan. Prabhu Rajagopalan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alvarado, Yesid, Rachel J. Cook, Shira Dinner, et al.. (2025). The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia. PubMed. 2(3). 100108–100108. 1 indexed citations
2.
Davids, Matthew S., Danielle M. Brander, Yesid Alvarado, et al.. (2024). A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies. Blood Advances. 9(4). 820–832. 3 indexed citations
3.
Boland, Patrick M., Heinz‐Josef Lenz, Kristen K. Ciombor, et al.. (2024). A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer. Investigational New Drugs. 43(1). 60–68. 2 indexed citations
4.
Soumerai, Jacob D., Catherine Diefenbach, Adam Asch, et al.. (2024). Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. British Journal of Haematology. 204(5). 1762–1770. 3 indexed citations
5.
Bulat, Iurie, Kathleen N. Moore, John Chung, et al.. (2018). Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.. Journal of Clinical Oncology. 36(15_suppl). 5571–5571. 13 indexed citations
6.
Joerger, Markus, Ross A. Soo, Byoung Chul Cho, et al.. (2017). A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study. Annals of Oncology. 28. v126–v127. 2 indexed citations
7.
Bahleda, Rastislav, Juneko E. Grilley‐Olson, Ramaswamy Govindan, et al.. (2017). Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer. 116(12). 1505–1512. 22 indexed citations
8.
9.
Adjei, Alex A., Donald Richards, Anthony B. El-Khoueiry, et al.. (2015). A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clinical Cancer Research. 22(10). 2368–2376. 16 indexed citations
10.
11.
12.
Weekes, Colin D., Daniel D. Von Hoff, Alex A. Adjei, et al.. (2013). Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer. Clinical Cancer Research. 19(5). 1232–1243. 46 indexed citations
13.
Bahleda, Rastislav, Anas Gazzah, Andréa Varga, et al.. (2012). A first-in-human phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 3 days on/4 days off schedule.. Journal of Clinical Oncology. 30(15_suppl). 3012–3012. 6 indexed citations
14.
Mross, K., Annette Frost, M. E. Scheulen, et al.. (2011). Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer. PubMed. 3(1). 16–16. 10 indexed citations
15.
Blumenschein, G. R., Julian R. Molina, Chetan Lathia, et al.. (2011). Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 29(15_suppl). 7565–7565. 1 indexed citations
16.
Meza–Junco, Judith, Quincy S. Chu, Olaf Christensen, et al.. (2009). UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemotherapy and Pharmacology. 65(1). 1–4. 52 indexed citations
17.
Davey, Richard T., Peter Pertel, Alice Benson, et al.. (2008). Safety, Tolerability, Pharmacokinetics, and Efficacy of an Interleukin-2 Agonist Among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. Journal of Interferon & Cytokine Research. 28(2). 89–100. 5 indexed citations
18.
Gelderblom, Hans, Jaco J. Verweij, Neeltje Steeghs, et al.. (2006). 72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors. European Journal of Cancer Supplements. 4(12). 26–26. 3 indexed citations
19.
20.
Rajagopalan, Prabhu, et al.. (1996). Pharmacokinetics of (—)-β-L-2′,3′-Dideoxy-3′-thiacytidine in Rats. Pharmacy and Pharmacology Communications. 2(3). 133–136. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annamaria Catino Breakdown of academic impact, for papers by Lucille Leong Breakdown of academic impact, for papers by Zaina T. Al-Salama Breakdown of academic impact, for papers by Raffaele Longo Breakdown of academic impact, for papers by Rakesh Goel Breakdown of academic impact, for papers by Virginia E. Kwitkowski Breakdown of academic impact, for papers by Martin A. Graham Breakdown of academic impact, for papers by Yoichiro Kakugawa Breakdown of academic impact, for papers by Jianwei Zhang Breakdown of academic impact, for papers by Jiang Liu
Rankless by CCL
2026